
From: [Art 4.1(b)] (TRADE)
Sent: Thursday, September 06, 2018 5:44 PM
To: [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE)
Cc: [Art 4.1(b)] (TRADE); [Art 4.1(b)] (TRADE); VERLY Johan (CAB-MALMSTROM);
BURGSMUELLER Christian (CAB-MALMSTROM)
Subject: FLASH: meeting HoC Mia Åsenius and Eli Lilly [Art 4.1(b)]

Today Head of Cabinet Ms Åsenius met the [Art 4.1(b)] of Eli Lilly (a multinational pharmaceutical company) Mr [Art 4.1(b)] ([Art 4.1(b)]
[Art 4.1(b)] .

The main subject of the meeting was the EU-US trade relations, with a specific focus on the intellectual property (IP). Overall, the pharma industry is one of the main advocates for a stronger EU-US cooperation. [Art 4.1(a)]

Mr [Art 4.1(b)] highlighted that the pharma industry has one main interest in trade agreements – a strong IP chapter. Therefore, an EU-US agreement should also have such a chapter. Ms Åsenius explained that it is not foreseen to re-start TTIP negotiations and an agreement of more restricted scope would have more chances of being agreed.

The rest of the document is redacted as out of scope

[Art 4.1(b)]

<< OLE Object: Picture (Device Independent Bitmap) >>

European Commission
Directorate General Trade
Unit B3 Intellectual Property and Public Procurement
1049 Brussels, Belgium

office: CHAR[Art 4.1(b)], tel.: +32-2-2 [Art 4.1(b)]

e-mail: [Art 4.1(b)] [@ec.europa.eu](mailto:[Art 4.1(b)]@ec.europa.eu)

The views expressed in this e-mail are my own and may not,
under any circumstances, be interpreted as stating an official
position of the European Commission.